{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darbepoetin", "query": { "intervention": "Darbepoetin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darbepoetin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T04:12:03.791Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00058422", "title": "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "darbepoetin alfa", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "indium In 111 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "60 Years to 120 Years" }, "enrollment_count": 65, "start_date": "2003-02-10", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058422" }, { "nct_id": "NCT01222195", "title": "Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-02", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222195" }, { "nct_id": "NCT03457701", "title": "Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Ferrous sulfate containing the stable iron isotope (57Fe)", "type": "DRUG" }, { "name": "Ferrous sulfate containing the stable iron isotope (58Fe)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-07-30", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 3, "location_summary": "Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" }, { "city": "Lufkin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03457701" }, { "nct_id": "NCT00146562", "title": "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Stage I Breast Cancer", "Stage II Breast Cancer" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harold J. Burstein, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2003-07", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2023-08-02", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lowell", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00146562" }, { "nct_id": "NCT00598442", "title": "Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Renal Failure", "Chronic Kidney Disease", "Anemia" ], "interventions": [ { "name": "peginesatide", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affymax", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 493, "start_date": "2007-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Granada Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598442" }, { "nct_id": "NCT00283621", "title": "Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Aranesp (darbepoetin alfa)", "type": "DRUG" }, { "name": "Neulasta (pegfilgrastim)", "type": "DRUG" }, { "name": "Adriamycin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2003-06-02", "completion_date": "2006-04-12", "has_results": false, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283621" }, { "nct_id": "NCT00386152", "title": "A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Anemia", "Cancer" ], "interventions": [ { "name": "epoetin alfa", "type": "DRUG" }, { "name": "darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2006-11", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 76, "location_summary": "Glendale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 73 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00386152" }, { "nct_id": "NCT00598273", "title": "Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Renal Failure", "Chronic Kidney Disease", "Anemia" ], "interventions": [ { "name": "peginesatide", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affymax", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2007-10", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 68, "location_summary": "Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598273" }, { "nct_id": "NCT03071861", "title": "Mild Encephalopathy in the Newborn Treated With Darbepoetin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neonatal Encephalopathy", "Hypoxic-Ischemic Encephalopathy Mild" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Hour", "maximum_age": "24 Hours", "sex": "ALL", "summary": "1 Hour to 24 Hours" }, "enrollment_count": 28, "start_date": "2017-12-01", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071861" }, { "nct_id": "NCT00355407", "title": "Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2006-06", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2009-03-13", "last_synced_at": "2026-09-05T04:12:03.791Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00355407" } ] }